A detailed history of Pro Share Advisors LLC transactions in Recursion Pharmaceuticals, Inc. stock. As of the latest transaction made, Pro Share Advisors LLC holds 61,311 shares of RXRX stock, worth $378,901. This represents 0.0% of its overall portfolio holdings.

Number of Shares
61,311
Previous 32,877 86.49%
Holding current value
$378,901
Previous $246,000 64.23%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$5.92 - $8.6 $168,329 - $244,532
28,434 Added 86.49%
61,311 $404,000
Q2 2024

Aug 13, 2024

SELL
$7.35 - $10.05 $59,329 - $81,123
-8,072 Reduced 19.71%
32,877 $246,000
Q1 2024

May 08, 2024

BUY
$9.13 - $15.52 $46,115 - $78,391
5,051 Added 14.07%
40,949 $408,000
Q4 2023

Feb 14, 2024

BUY
$5.09 - $10.79 $24,579 - $52,104
4,829 Added 15.54%
35,898 $353,000
Q3 2023

Nov 13, 2023

BUY
$6.59 - $15.86 $9,041 - $21,759
1,372 Added 4.62%
31,069 $237,000
Q2 2023

Aug 10, 2023

BUY
$4.56 - $9.94 $4,081 - $8,896
895 Added 3.11%
29,697 $221,000
Q1 2023

May 11, 2023

SELL
$6.42 - $9.64 $24,453 - $36,718
-3,809 Reduced 11.68%
28,802 $192,000
Q4 2022

Feb 02, 2023

BUY
$7.16 - $12.7 $26,542 - $47,078
3,707 Added 12.83%
32,611 $251,000
Q3 2022

Nov 04, 2022

BUY
$7.83 - $13.6 $7,469 - $12,974
954 Added 3.41%
28,904 $308,000
Q2 2022

Aug 01, 2022

SELL
$5.04 - $9.26 $51,191 - $94,053
-10,157 Reduced 26.65%
27,950 $227,000
Q1 2022

May 10, 2022

SELL
$6.16 - $18.03 $58,778 - $172,042
-9,542 Reduced 20.03%
38,107 $272,000
Q4 2021

Feb 08, 2022

BUY
$16.14 - $21.86 $769,054 - $1.04 Million
47,649 New
47,649 $816,000
Q3 2021

Nov 12, 2021

SELL
$19.03 - $41.33 $104,322 - $226,571
-5,482 Closed
0 $0
Q2 2021

Aug 13, 2021

BUY
$18.0 - $37.42 $98,676 - $205,136
5,482 New
5,482 $200,000

Others Institutions Holding RXRX

About RECURSION PHARMACEUTICALS, INC.


  • Ticker RXRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 180,480,000
  • Market Cap $1.12B
  • Description
  • Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...
More about RXRX
Track This Portfolio

Track Pro Share Advisors LLC Portfolio

Follow Pro Share Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pro Share Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pro Share Advisors LLC with notifications on news.